A pilot study using point-of-care ultrasound (POCUS) of the inferior vena cava (IVC) found severe hypervolemia in 20% of patients after intravenous (IV) albumin, despite adherence to current guidelines. The gene discussed is ALB; the disease is Hypervolemia.